

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/553,001
		Filing Date	July 24, 2006
		First Named Inventor	Barbara A. Gilchrest
		Group Art Unit	1635
		Examiner Name	Zara, Jane J.
Sheet	1	of	8
		Attorney Docket Number	06225.0004.PCUS00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A1	3,937,809	02-10-1976	Jacobi, O.K.	
	A2	4,419,343	12-06-1983	Pauly, M.	
	A3	4,508,703	04-02-1985	Redziniak, et al.	
	A4	4,621,023	11-04-1986	Redziniak, et al.	
	A5	5,077,211	12-31-1991	Yarosh, D.B.	
	A6	5,256,648	10-26-1993	Gasparro, et al.	
	A7	5,455,029	10-03-1995	Hartman, et al.	
	A8	5,470,577	11-28-1995	Gilchrest, et al.	
	A9	5,489,508	02-06-1996	West, et al.	
	A10	5,532,001	07-02-1996	Gilchrest, et al.	
	A11	5,580,547	12-03-1996	Gilchrest, et al.	
	A12	5,583,016	12-10-1996	Villeponteau, et al.	
	A13	5,585,479	12-17-1996	Hoke, et al.	
	A14	5,599,672	02-04-1997	Liang, et al.	
	A15	5,643,556	07-01-1997	Gilchrest, et al.	
	A16	5,643,890	07-01-1997	Iversen, et al.	
	A17	5,645,986	07-08-1997	West, et al.	
	A18	5,686,306	11-11-1997	West, et al.	
	A19	5,837,857	11-17-1998	Villaponteau, et al.	
	A20	5,858,987	01-12-1999	Beer-Romero, et al.	
	A21	5,879,713	03-09-1999	Roth, et al.	
	A22	5,955,059	09-21-1999	Gilchrest, et al.	
	A23	6,007,989	12-28-1999	West, et al.	
	A24	6,015,710	01-18-2000	Shay, et al.	
	A25	6,020,138	02-01-2000	Akhavan-Tafti	
	A26	6,046,307	04-04-2000	Shay, et al.	
	A27	6,103,243	08-15-2000	Russell-Jones, et al.	
	A28	6,147,056	11-14-2000	Gilchrest, et al.	
	A29	6,194,206	02-27-2001	West, et al.	
	A30	6,320,039	11-20-2001	Villeponteau, et al.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DM_US/8047872.v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/553,001	
				Filing Date	July 24, 2006	
				First Named Inventor	Barbara A. Gilcrest	
				Group Art Unit	1635	
Examiner Name	Zara, Jane J.					
Attorney Docket Number	06225.0004.PCUS00					
Sheet	2	of	8			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A31	6,440,650	08-27-2002	Matsuda, et al.	
	A32	7,033,829	04-25-2006	Gilcrest, et al.	
	A33	7,094,766	08-22-2006	Gilcrest, et al.	
	A34	7,200,531	04-03-2007	Phillips, et al.	

U.S. PUBLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A35	2003/0144233	07-31-2003	Phillips, et al.	
	A36	2003/0032611	02-13-2003	Gilcrest, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ¹ , Number ⁴ , Kind Code ⁵ (if known)				
	B1	AU 717296	06-03-1996	Bio Merieux		
	B2	CA 2,224,150	12-12-1996	Trustees of Boston University		
	B3	EP 0 035 384 A2	09-09-1981	Rutter		
	B4	GB 2 336 157 A	10-13-1999	Trustees of Boston University		
	B5	WO 93/09788	05-27-1993	Baylor College of Medicine		
	B6	WO 93/12230	06-24-1993	SRI International		
	B7	WO 93/22431	11-11-1993	Baylor College of Medicine		
	B8	WO 94/08053	04-14-1994	ISIS Pharmaceuticals, Inc.		

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/553,001
				Filing Date	July 24, 2006
				First Named Inventor	Barbara A. Gilcrest
				Group Art Unit	1635
Examiner Name	Zara, Jane J.				
Attorney Docket Number	06225.0004.PCUS00				
Sheet	3	of	8		

	B9	WO 95/01773	01-19-1995	Trustees of Boston University		
	B10	WO 95/07362	03-16-1995	Public Health Laboratory Service Board		
	B11	WO 95/09175	04-06-1995	Burns, et al.		
	B12	WO 96/23508	08-08-1996	Board of Regents of the University of Nebraska		
	B13	WO 96/27131	09-06-1996	E. Salonen		
	B14	WO 96/39152	12-12-1996	Trustees of Boston University		
	B15	WO 96/40989	12-19-1996	Bio Merieux		
	B16	WO 97/08314	08-23-1996	The Rockefeller University		
	B17	WO 97/20924	06-12-1997	Saicom S.R.L. Scaggiante		
	B18	WO 97/38013	10-16-1997	Geron Corporation		
	B19	WO 97/44450	11-27-1997	Yale University		
	B20	WO 98/06702	02-19-1998	Bayer Aktiengesellschaft	Abstract	
	B21	WO 98/36066	08-20-1998	The Rockefeller University		
	B22	WO 99/03507	01-28-1999	Board of Regents of the University of Nebraska		
	B23	WO 01/18015	03-15-2001	Geron Corporation		
	B24	WO 01/44465	06-21-2001	Bioniche Life Sciences Inc.		
	B25	WO 01/74342	10-11-2001	Trustees of Boston University		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/553,001
		Filing Date	July 24, 2006
		First Named Inventor	Barbara A. Gilchrist
		Group Art Unit	1635
		Examiner Name	Zara, Jane J.
(use as many sheets as necessary)	Attorney Docket Number 06225.0004.PCUS00		
Sheet	4	of	8

C1	Akiyama, M., et al., "Cytostatic Concentrations of Anticancer Agents do not Affect Telomerase Activity of Leukaemic Cells in Vitro," European Jour. of Cancer, 35(2):309-315 (1999)	
C2	Anderson, W.F., "Human Gene Therapy," Nature, Vol. 392, pp. 25-30 (April 1998)	
C3	Balasubramanian, S., et al., "Activation of telomerase and its association with G1-phase of the Cell Cycle During UVB-Induced Skin Tumorigenesis in SKH-1 Hairless Mouse," Oncogene, 18:1297-1302 (1999)	
C4	Balabhadrapathruni, S., et al., "Growth Inhibitory Effects of a Telomeric Oligonucleotide on MCF-7 Breast Cancer Cells," Abstract No. 3388	
C5	Beckman, K.B., et al., "The Free Radical Theory of Aging Matures," Physiol Rev, Vol. 78, No. 2, pp. 547-581 (1998).	
C6	Beltz, L., et al., "The Effects of Telomerase Inhibitors on Lymphocyte Function," Anticancer Research, 19:3205-3212 (1999)	
C7	Branch, A.D., "A Good antisense Molecule is Hard to Find," TIBS, Vol. 23, pp. 45-50 (1998)	
C8	Chang, G.G., et al., "Inhibition of Human Cancer cell Growth by Periodate-oxidized 3-Aminopyridine Adenine Dinucleotide Diphosphate," International J. of Bio Chem., Vol. 22, No. 11, pp. 1259-1269 (1990)	
C9	Chen, L., et al., "WRN, the Protein Deficient in Werner Syndrome, Plays a Critical Structural Role in Optimizing DNA Repair," Aging Cell, Vol. 2, pp. 191-199 (2003)	
C10	Chen, Q., et al., "Oxidative DNA Damage and Senescence of Human Diploid Fibroblast Cells," Proc Natl Acad Sci USA Vol. 92, pp. 4337-4341 (1995).	
C11	Cruz, P.D., et al., "Thymidine Dinucleotides Inhibit Contact Hypersensitivity and Activate the Gene for tumor Necrosis Factor α ," J. Investigative Dermatology, 114, pp. 253-258 (2000)	
C12	de Vries, T. J., et al., "Expression of gp100, MARTA-1, Tyrosinase and S100 in Paraffin-Embedded Primary Melanomas and Locoregional, Lymph Node, and Visceral Metastases: Implications for Diagnosis and Immunotherapy. A Study conducted by the EORTC Melanoma Cooperative Group," J. Pathology, Vol. 193, pp. 13-20 (2001)	
C13	Ding, S., et al., "Genetic Variation in the Premature Aging Gene WRN: A Case-Control Study on Breast Cancer Susceptibility," Cancer Epidemiol Biomarkers Prev., Vol. 16, No. 2, pp. 263-269 (2007)	
C14	El-Deiry, W.S., et al., "WAF1, a Potential Mediator of p53 Tumor Suppression," Cell, 75:817-825 (1993)	
C15	Eller, M.S., et al., "The Effect of Oligonucleotide Size and 5001' Phosphate on Stimulation of Melanogenesis," Journal of Investigative Dermatology," Abstract No. 113, Vol. 112(4):541 (1999)	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/553,001
				Filing Date	July 24, 2006
				First Named Inventor	Barbara A. Gilchrist
				Group Art Unit	1635
				Examiner Name	Zara, Jane J.
(use as many sheets as necessary)				Attorney Docket Number	06225.0004.PCUS00
Sheet	5	of	8		

	C16	Eller, M.S., et al., "Induction of Apoptosis by Telomere' Overhang-Specific DNA," Experimental Cell Research, Vol. 276, pp. 185-193 (2002)	
	C17	Eller, M.S., et al., "Enhancement of DNA Repair in Human Skin Cells by Thymidine Dinucleotides: Evidence for a p53-Mediated Mammalian SOS Response," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 12627-12632 (1997)	
	C18	Eller, M.S., et al., "Activation of p53 Tumor Suppressor Protein by Thymidine Dinucleotides," Annual Meeting Of the Society for Investigative Dermatology, Journal of Investigative Dermatology, Vol. 106, No. 4, p. 835 (1996) XP002014518	
	C19	Fritsche, M., et al., "Induction of Nuclear Accumulation of the Tumor-Suppressor Protein p53 by DNA-damaging Agents," Oncogene 8:307-318 (1993)	
	C20	Gerwitz, et al., Blood, Vol. 92, No. 3, pp. 712-736 (1998)	
	C21	Gomez-Navarro, et al., "Gene Therapy for Cancer, European Journal of Cancer, Vol. 35, pp. 867-885 (1999)	
	C22	Goukassian, et al., "DNA Oligonucleotide Treatment Corrects the Age-Associated Decline in DNA Repair Capacity, FASEB J., Vol. 16, No. 7, pp. 754-756 (2002)	
	C23	Goukassian, D.A. et al., "Topical DNA Oligonucleotide Therapy Reduces UV-induced Mutations and Photocarcinogenesis in Hairless Mice," Proc Natl Acad Sci USA, Vol. 101, No. 11, pp. 3933-3938 (2004).	
	C24	Hadshiew, I.M., et al., "Stimulation of Malenogenesis by DNA Oligonucleotides: Effect of Size, Sequence and 5' Phosphorylation," Journal of Dermatological Science, pp. 127-138 (2001)	
	C25	Harley, C.B., et al., "Telomerase, Checkpoints and Cancer," In Cancer Surveys - Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology, Cold Spring Harbor Laboratory Press, 29:263-284 (1997)	
	C26	Ho, P., et al., "Antisense Oligonucleotides as Therapeutics for Malignant Disease," Vol. 24, No. 2, pp. 187-202 (April 1997)	
	C27	Hupp, T.R., et al., "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53," Cell, 83:237-245 (1995)	
	C28	International Searching Authority (ISA/US), "Written Opinion," July 17, 2007, of PCT/US06/12468 filed April 4, 2005	
	C29	Jayaraman, L., et al., "Activation of p53 Sequence-Specific DNA Binding by Short Single Strands of DNA Requires the p53 C-Terminus," Cell, 81:1021-1029 (1995)	
	C30	Jen, et al., Stem Cells, Vol. 18, pp. 307-319 (2000)	
	C31	Kastan, M.B., et al., "A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia," Cell, 71:587-597 (1992)	
	C32	Kern, S.E., et al., "Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression," Science, 256:827-830 (1992)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/553,001
				Filing Date	July 24, 2006
				First Named Inventor	Barbara A. Gilchrist
				Group Art Unit	1635
				Examiner Name	Zara, Jane J.
(use as many sheets as necessary)				Attorney Docket Number	06225.0004.PCUS00
Sheet	6	of	8		

C33	Li, G.Z., et al., "Evidence that Exposure of the Telomere 3' Overhang Sequence Induces Senescence," Proc Natl Acad Sci USA, Vol. 100, pp. 527-531 (2003).	
C34	Lu, et al., in RNA Interference Technology (Cambridge, Appasani ed.) (2005)	
C35	Lu, X., et al., "Differential Induction of Transcriptionally Active p53 Following UV or Ionizing Radiation: Defects in Chromosome Instability Syndromes?" Cell, 75:765-778 (1993)	
C36	Maeda, T., et al., "Enhanced Repair of Benzo(a)pyrene-induced DNA Damage in Human Cells Treated with Thymidine Dinucleotides, Mutat Res, Vol. 433, pp. 137-145 (1999).	
C37	Magnoni, C., et al., "Thymidine Dinucleotides Enhance DNA Repair in Normal Human Skin Cells," Annual Meeting of the Society for Investigative Dermatology, Journal of Investigative Dermatology 106 (4), 1996 XP002014517	
C38	Mata, J., et al., "A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cells in Vitro and in Viv," Toxicol. Appl. Pharmacol. 144:189-197 (1997).	
C39	Melnikova, V.O., et al., Mutation Research., Vol. 571, pp. 91-106 (2005)	
C40	Mitchell, D.L. et al., "The Induction and Repair of DNA Photodamage in The Environment," In Environment UV Photobiology, A.R. Young, et al., eds. (Ny: Plenum Press), pp. 345-377 (1993)	
C41	Mitsudomi, T., et al., "p53 Gene Mutations in Non-Small-Cell Lung Cancer cell Lines and Their Correlation With The Presence of ras Mutations and Clinical Features," Oncogene 7:171-180 (1992)	
C42	Nelson, W.G., et al., "DNA Strand Breaks: The DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways," Mol. And Cell. Biol. 14(3):1815-1823 (1994)	
C43	Nicolaus, B.J.R., "Symbiotic Approach to Drug Design, Decision Making in Drug Research, pp. 173-186 (1983)	
C44	Niggli, H.J., et al., "Sunlight-Induced Pyrimidine Dimers in Human Skin Fibroblasts in Comparison With Dimerization After Artificial UV-Irradiation," Photochemistry and Photobiology, 48(3):353-356 (1988)	
C45	Norton, J.E., et al., "Inhibition of Human Telomerase Activity by Peptide Nucleic Acids," Nature Biotechnology, Vol. 14, pp. 615-619 (1996)	
C46	Ohnuma, T., et al., "Inhibitory Effects of Telomere-Mimic Phosphorothioate Oligonucleotides on Various Human Tumor Cells in Vitro, Anticancer Research, No. 17, pp. 2455-2458 (1997)	
C47	Orkin, et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Distributed by the National Institutes of Health, December 7, 1995	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/553,001
				Filing Date	July 24, 2006
				First Named Inventor	Barbara A. Gilchrist
				Group Art Unit	1635
				Examiner Name	Zara, Jane J.
(use as many sheets as necessary)				Attorney Docket Number	06225.0004.PCUS00
Sheet	7	of	8		

	C48	Page, D.T., et al., "Innovations in Oral Gene Delivery: Challenges and Potentials," Vol. 6, No. 2, pp. 92-101 (Jan. 2001)	
	C49	Page, T.J., et al., "The Cytotoxic Effects of Single-Stranded Telomere Mimics on OMA-BL1 Cells," No. 252, pp. 41-49 (1999)	
	C50	Parris, C.N., et al., "Telomerase Activity in Melanoma and Non-Melanoma Skin Cancer," British Jour. Of Cancer, 79(1):47-53 (1999)	
	C51	Pedoux, R., et al., "Thymidine Dinucleotides Induce S Phase Cell Cycle Arrest in Additional to Increased Melanogenesis in Human Melanocytes," Journal of Investigative Dermatology, 111:472-477 (1998)	
	C52	Plenat, F., "Animal Models of Antisense Oligonucleotides: Lessons for Use in Humans," Molecular Medicine Today, June 1996, pp. 250-257	
	C53	Saeki, T., et al., "Inhibitory Effect of Telomere-Mimic Phosphorothioate Oligodeoxy Nucleotides (S-ODNS) in Human Tumor Cell Lines," Oncology, Vol. 57, pp. 27-36 (1999)	
	C54	Sanchez, Y., et al., "Regulation of RAD53 by the ATM-Like Kinases MEC1 and TEL1 in Yeast Cell Cycle Checkpoint Pathways," Science, 271:357-360 (1996)	
	C55	Saeki, T., et al., "Inhibitory Effect of Telomere-Mimic Phosphorothioate Oligodeoxy Nucleotides (S-ODNS) in Human Tumor Cell Lines," Oncology, Vol. 57, pp. 27-36 (1999)	
	C56	Sanchez, Y., et al., "Regulation of RAD53 by the ATM-Like Kinases MEC1 and TEL1 in Yeast Cell Cycle Checkpoint Pathways," Science, 271:357-360 (1996)	
	C57	Saretzki, G., et al., "Telomere Shortening Triggers a p53-Dependent Cell Cycle Arrest Via Accumulation of G-Rich Single Stranded DNA Fragments," Oncogene, Vol. 18, pp. 5148-5158 (1999)	
	C58	Stull, R.A., et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Vol. 12, No. 4, pp. 465-483 (1995)	
	C59	Verma, I.M., et al., "Gene Therapy-Promises, Problems and Prospects," Nature, Vol. 389, pp. 239-242 (Sep. 1997)	
	C60	Voet, D., et al., "DNA Replication, Repair and Recombination," Biochemistry, Chap. 31, pp. 967-972 (1990)	
	C61	Walworth, N.C. et al., "rad-Dependent Response of the chk1-Encoded Protein Kinase at the DNA Damage Checkpoint," Science, 271:353-356 (1996)	
	C62	Wei, Q., et al., "DNA Repair and Aging in Basal Cell Carcinoma: A Molecular Epidemiology Study," Proc. Natl. Acad. Sci. USA 90:1614-1618 (1993)	
	C63	White, et al., "Principles of Biochemistry," 6th Edition, pps. 182-183 (1978)	
	C64	Wright, W.E., et al., "Experimental Elongation of Telomeres Extends the lifespan of immortal x normal cell hybrids," The EMBO Journal, 15(7):1734-1741 (1996)	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/553,001
		Filing Date	July 24, 2006
		First Named Inventor	Barbara A. Gilcrest
		Group Art Unit	1635
		Examiner Name	Zara, Jane J.
		Attorney Docket Number	06225.0004.PCUS00
(use as many sheets as necessary)			
Sheet	8	of	8

C65	WU, K., et al., "Telomerase Activity and Telomere Length in Lymphocytes from patients with Cutaneous T-Cell Lymphoma," Cancer, 86(6):1056-1063 (1999)	
C66	Yaar, M., et al., "Aging Versus Photoaging: Postulated Mechanisms and Effectors," The Society for Investigative Dermatology Symposium Proceedings, 3:47-51 (1998)	
C67	Yaar, M., et al., "The trk Family of Receptors Mediates Nerve Growth Factor and Neurotrophin-3 Effects in Melanocytes," J. Clin. Invest 94:1550-1562 (1994)	
C68	08/467,012 - Non-final office action dated 09-17-1996	
C69	08/467,012 - Non-final office action dated 06-10-1997	
C70	08/467,012 - Final office action dated 01-21-1998	
C71	08/467,012 - Notice of Allowance dated 03-16-1999	
C72	09/048,927 - Non-final office action dated 06-15-1999	
C73	09/048,927 - Final office action dated 01-12-2000	
C74	09/048,927 - Notice of Allowance dated 06-20-2000	
C75	09/540,843 - Restriction Requirement dated 07-03-2001	
C76	09/540,843 - Restriction Requirements dated 09-20-2001	
C77	09/540,843 - Non-final action dated 03-15-2002	
C78	09/540,843 - Non-final office action dated 11-18-2002	
C79	09/540,843 - Non-final office action dated 08-12-2003	
C80	09/540,843 - Final office action dated 02-26-2004	
C81	09/540,843 - Final office action dated 05-10-2005	
C82	09/540,843 - Non-final office action dated 08-24-2005	
C83	09/540,843 - Notice of Allowance and Examiner's amendment dated 03-02-2006	
C84	10/122,630 - Restriction Requirement dated 11-21-2003	
C85	10/122,630 - Non-final office action dated 02-01-2006	
C86	10/122,630 - Final office action dated 10-19-2006	
C87	10/122,630 - Advisory action dated 03-19-2007	
C88	10/122,633 - Restriction Requirement dated 10-06-2004	
C89	10/122,633 - Non-final office action dated 02-23-2005	
C90	10/122,633 - Notice of Allowance dated 09-21-2005	
C91	11/195,088 - Restriction Requirement dated 03-17-2006	
C92	11/195,088 - Non-final action dated 06-13-2006	
C93	11/195,088 - Final office action dated 03-12-2007	
C94	11/195,088 - Non-final office action dated 05-20-2008	
C95	11/185,088 - Final office action dated 01-29-2009	
C96	11/409,706 - Non-final office action dated 05-18-2007	
C97	11/409,706 - Final office action dated 02-07-2008	
C98	11/409,706 - Non-final office action dated 11-13-2008	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place mark here if English language Translation is attached

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.